Novavax Inc. ($NVAX) Stock Forecast: Down 5.1% Today

What is Novavax Inc.?

Novavax Inc. (NVAX) is a biotechnology company focusing on vaccine development, particularly for infectious diseases like COVID-19. The stock experienced a decrease in value today amidst market fluctuations.

Why is Novavax Inc. going down?

NVAX stock is down 5.1% on Mar 24, 2026 18:45

• Novavax's stock showed minimal growth but lagged behind the overall market performance, hinting at negative investor sentiment.
• Regulatory filings by the company disclosed significant occurrences such as payments for milestones, FDA nods, and financial operations, potentially impacting market perception.
• Challenges persist for Novavax, including consecutive days of losses and weaker performance relative to industry peers, raising investor apprehensions.
• With a neutral "Hold" rating from brokerage firms, surpassing earnings, and heightened institutional investor interest, the stock displays a mixed outlook, prompting cautious market behavior.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax Inc. stock rises Monday, still underperforms market

Novavax Inc. (NVAX) stock increased by 1.04% to $9.72 on Monday, breaking a three-day losing streak. Despite this gain, the stock underperformed the broader market, as both the NASDAQ Composite Index and the Dow Jones Industrial Average saw larger increases of 1.38%.

https://www.marketwatch.com/data-news/novavax-inc-stock-rises-monday-still-underperforms-market-b8b7b3d5-d862c14c1486?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqfeH0TjdAJ0oXEBlPL6oRnrE0xhNX6Y5pPGX7-I2FOBeWs3mcUw4vN1&gaa_ts=69c27491&gaa_sig=3InEdxTcfUTZLXdsLXwTufShkmZzIv_N-1bKHy_qAKbzSBlIjX8ZoSqutXxQWrSZkqpDyPEvz77jJHi6tNAyNg%3D%3D

NVAX SEC Filings - Novavax Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Novavax (NVAX) SEC filings, including annual reports (10-K), quarterly reports (10-Q), and material event reports (8-K). It details recent significant events such as milestone payments from Sanofi, FDA approvals for COVID-19 vaccines, and convertible note transactions that impact the company's financial structure. The platform also offers AI-powered summaries of these documents to help investors understand their implications.

https://www.stocktitan.net/sec-filings/NVAX/page-4.html

NVAX SEC Filings - Novavax Inc 10-K, 10-Q, 8-K Forms

This page provides access to Novavax Inc.'s SEC filings, including 10-K, 10-Q, and 8-K forms, offering investors detailed regulatory disclosures. It highlights key events like executive stock transactions, collaboration agreements with companies like Pfizer and Sanofi, and financial reports with AI-powered summaries for easier understanding. The filings cover various material events, financial performance, and insider activities, updated in near real-time.

https://www.stocktitan.net/sec-filings/NVAX/page-3.html

Novavax Inc. stock underperforms Thursday when compared to competitors

Novavax Inc. (NVAX) shares dropped 2.70% to $9.74 on Thursday, contributing to its second consecutive day of losses. This underperformance occurred during a generally negative trading session, with both the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing declines.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-thursday-when-compared-to-competitors-734f0908-e6d6ce7b3052?gaa_at=eafs&gaa_n=AWEtsqcuHlIRXGrj4lS4lbJvo_ZXvK5FzAWQF0JKcaijuq05qp7bOYg3TWR0&gaa_ts=69bdc1fd&gaa_sig=1AHxPfh7w97VIV1QnVS_vgzyQgK6sxRM7yO7d5MHC5Bk9l5unFMc_mOnN-S2OanNx3fYqV0Rl09VsumPlprLHQ%3D%3D

Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Brokerages

Novavax, Inc. (NASDAQ:NVAX) has received a consensus "Hold" rating from ten brokerages, with an average 12-month price target of $11.88. The company recently reported better-than-expected earnings of $0.11 EPS against an anticipated -$0.66, and revenue of $136.4 million, marking a 66.6% year-over-year increase. Despite institutional investors increasing their stakes, the stock's market capitalization stands at $1.63 billion with a high debt-to-equity ratio of 5.93.

https://www.marketbeat.com/instant-alerts/novavax-inc-nasdaqnvax-given-average-rating-of-hold-by-brokerages-2026-03-19/

Trending Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.3% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 9.0% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 5.1% Today

Verisk Analytics Inc. ($VRSK) Stock Forecast: Down 5.0% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Down 5.4% Today

Waters Corporation ($WAT) Stock Forecast: Down 0.7% Today

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 5.4% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 6.8% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Up 11.0% Today

Xerox Corporation ($XRX) Stock Forecast: Up 5.3% Today

Novavax Inc. Price History

03.02.2026 - NVAX Stock was down 5.7%

• Novavax's stock plummeted over 10% due to Sanofi taking over commercial responsibility for its COVID vaccine in selected markets, excluding future revenue from 2026 projections.
• Analysts maintained cautious ratings of "Underperform" and "Sell" despite slight price target increases, reflecting concerns about the company's financial challenges and strategic uncertainties.
• Negative sentiment surrounding Novavax's stock was fueled by low revenue guidance for 2026, along with restructuring and job cuts.
• Novavax's shares were also impacted by inflationary pressures and concerns about potential delays in interest rate cuts by the Federal Reserve, following a recent gain driven by strong financial results.

04.02.2026 - NVAX Stock was up 5.3%

• Today's positive movement in NVAX's stock could be tied to the CFO's reception of Restricted Stock Units (RSUs) and stock options, a signal of confidence in the company's future.
• Despite challenges like lower revenue guidance and negative ratings from analysts, the increase in earnings estimates and the company's involvement in upcoming investor events may have boosted investor confidence, driving the upward trend.
• The recent news of Sanofi taking on commercial responsibility for the Nuvaxovid vaccine in selected markets might have also contributed to the optimistic shift, potentially opening new revenue streams and market opportunities for Novavax.
• In summary, though NVAX's stock faces uncertainties and mixed financial forecasts, the upswing seen today hints at investor emphasis on long-term growth prospects and company advancements, overriding short-term hurdles.

18.02.2026 - NVAX Stock was down 5.1%

• Despite recent positive developments and analyst support, Novavax Inc. (NVAX) observed a significant 5.56% decrease in its stock price today.
• The increase in institutional investment by Farallon Capital Management LLC, acquiring a notable amount of shares, did not appear to enhance the stock's performance on the current day.
• The varied assessments from analysts, ranging from reaffirmed Buy ratings to optimistic price forecasts, might not have counteracted the broader market sentiment affecting Novavax's stock.
• It seems that notwithstanding the company's impressive earnings report and innovative platform, external market conditions or profit-taking activities could have played a role in today's downward trend for Novavax Inc.

24.01.2026 - NVAX Stock was up 5.3%

• NVAX stock experienced a bullish movement today.
• The collaboration between Novavax and GSK to provide manufacturing capacity for up to 60 million doses of the COVID-19 vaccine candidate highlights the company's commitment to expanding its global supply network.
• Novavax's focus on targeting Americans hesitant about mRNA vaccines with its protein-based technology, coupled with its recent profitability and potential for annual COVID-19 vaccinations, likely contributed to the positive market sentiment.
• The upcoming financial results announcement may also be generating optimism among investors regarding the company's performance and future prospects.

19.02.2026 - NVAX Stock was down 7.8%

• Novavax Inc.'s (NVAX) stock closed 5.92% lower at $10.01 today, showing a strong bearish movement.
• The underperformance of NVAX compared to its competitors and the broader market can be attributed to several factors:
• The company is projected to incur losses for the current quarter and fiscal year despite recent positive earnings surprises, impacting investor sentiment.
• Continuous days of losses, including today, may have led investors to take profits after benefiting from the stock's momentum previously.
• The increase in stake by institutional investors like Farallon Capital Management LLC in NVAX could indicate confidence in the company's long-term potential. However, the mixed analyst outlook and the stock closing below its 52-week high reflect ongoing market uncertainty.
• The bearish movement of NVAX today is a result of profit-taking, investor cautiousness due to projected losses, and the influence of broader market trends on the stock's performance.

20.02.2026 - NVAX Stock was up 5.5%

• Novavax (NVAX) stock saw a significant 5.56% surge to $10.64 today.
• This growth is linked to the company's recent earnings report surpassing expectations, with earnings of $0.11 EPS beating predictions of -$0.66 and a substantial 66.6% year-over-year revenue increase to $136.4 million.
• Although there have been days where the stock didn't perform as well as competitors and the overall market, positive investor sentiment regarding Novavax's earnings surprises and company interest contributed to today's rise.
• Investors are cautiously observing Novavax's high 5.93 debt-to-equity ratio and the average "Hold" rating from brokerages, signaling a wary outlook despite recent positive developments.

26.01.2026 - NVAX Stock was up 25.4%

• NVAX stock experienced a bullish movement likely due to anticipation of a 5.9% year-on-year revenue growth in the upcoming Q4 earnings.
• Despite expectations of wider quarterly losses, the market seems optimistic about Novavax's diversification efforts and strategic partnerships, such as the recent deal with Pfizer and GSK for manufacturing capacity.
• The collaboration with GSK to provide fill and finish capacity for up to 60 million doses of NVAX's COVID-19 vaccine in the UK showcases the company's commitment to expanding its global supply network, which could have positively influenced investor sentiment.
• The focus on moving away from sole reliance on the COVID-19 vaccine due to declining sales and expanding into oncology partnerships might have instilled confidence in the market regarding Novavax's long-term growth prospects.

24.02.2026 - NVAX Stock was down 5.1%

• Novavax's stock showed minimal growth but lagged behind the overall market performance, hinting at negative investor sentiment.
• Regulatory filings by the company disclosed significant occurrences such as payments for milestones, FDA nods, and financial operations, potentially impacting market perception.
• Challenges persist for Novavax, including consecutive days of losses and weaker performance relative to industry peers, raising investor apprehensions.
• With a neutral "Hold" rating from brokerage firms, surpassing earnings, and heightened institutional investor interest, the stock displays a mixed outlook, prompting cautious market behavior.

27.01.2026 - NVAX Stock was down 14.9%

• Novavax stock faced a bearish movement despite reporting Q4 revenue that beat expectations, indicating a disconnect between performance and market reaction.
• Investor questions at healthcare events may have raised concerns about the company's future growth prospects, leading to a sell-off in the stock.
• Anticipation of wider losses in Q4 earnings, despite revenue growth, could have contributed to the bearish sentiment among investors.
• The company's efforts to diversify beyond COVID-19 vaccines and focus on partnerships might not have resonated positively with investors, impacting the stock's performance negatively.

17.02.2026 - NVAX Stock was up 5.8%

• A substantial increase in stake by Farallon Capital Management LLC, which acquired 764,000 shares of NVAX, reflects a firm belief in the company's future potential, contributing to the stock's positive movement.
• Jefferies' reiterated support with a Buy rating and optimistic outlook on NVAX, highlighting the company's adjuvant platform and key partnerships, likely bolstered investor confidence and drove the stock's upward trajectory.
• Utilization of AI analysis to indicate positive sentiment and propose specific trading approaches for NVAX may have attracted a larger investor base, adding to the bullish momentum.
• Despite lagging behind competitors on Thursday, the overall positive sentiment surrounding NVAX, buoyed by institutional backing and analyst support, overshadowed the short-term decline and propelled the stock upwards.

12.02.2026 - NVAX Stock was down 5.1%

• The decline in NVAX stock today may be due to profit-taking by investors following a recent strong uptrend post the company's improved financial performance.
• Despite the positive developments such as moving to profits from losses in vaccine revenue and securing key partnerships, there could be investor concerns about the sustainability of these gains and potential obstacles in the vaccine market.
• Market uncertainties regarding NVAX's reliance on partner-driven milestones and royalties could be prompting some selling pressure on the stock.
• While NVAX's long-term strategy and partnerships show promise, short-term market sentiment and profit-taking actions may have influenced today's decline.

09.02.2026 - NVAX Stock was up 5.3%

• Novavax (NVAX) exhibited a bullish market movement following a significant improvement in its financial performance, transitioning from losses to profits in 2025 primarily due to increased vaccine revenues and effective cost control strategies.
• The company's recent licensing agreements with Pfizer and Sanofi have contributed to this positive momentum, leading to a return to profitability and surpassing revenue expectations.
• Despite being undervalued compared to its narrative fair value, Novavax's stock price has shown an upward trend, outperforming both the S&P 500 and its sector in the past month.
• The bullish sentiment towards Novavax is further bolstered by upward revisions in earnings estimates, although the company still maintains a Zacks Rank #3 (Hold) with a neutral short-term outlook.